Clario, a leading provider of digital endpoint data solutions to the clinical trial industry, announces completion of its acquisition of WCG’s electronic clinical outcome assessment (eCOA) business. This strategic move enhances Clario’s ability to provide best-in-class data collection and analysis solutions for neuroscience drug development, reinforcing its commitment to delivering high-quality, reliable data across all therapeutic areas. “I am excited to bring WCG’s eCOA team and technologies to Clario,” said Chris Fikry, M.D., chief executive officer, Clario. “Along with our recent acquisition of neurology imaging analysis experts, NeuroRx, we are positioned to be the true leader in delivering endpoint data solutions to neuroscience clinical trials.”
Read the full article: Clario Announces Completion of Acquisition of WCG’s eCOA Business //
Source: https://www.prnewswire.com/news-releases/clario-announces-completion-of-acquisition-of-wcgs-ecoa-business-302445925.html